LYVE-1, the lymphatic system and tumor lymphangiogenesis
2001 · Trends in Immunology · 355 citations
https://doi.org/10.1016/s1471-4906(01)01936-6
R
Remko Prevo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
119
Papers
7.9K
Citations
31
h-index
39
i10-index
Remko Prevo is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & DNA Repair Mechanisms & RNA modifications and cancer. The author has an h-index of 31, co-authored 102 publications.
ORCID: 0000-0001-5196-0552Papers by this author
worksTargeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
2012 · Cell Death and Disease · 353 citations
https://doi.org/10.1038/cddis.2012.181
Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met
1999 · Journal of Biological Chemistry · 226 citations
https://doi.org/10.1074/jbc.274.10.6499
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
2018 · Cell Death and Disease · 84 citations
https://doi.org/10.1038/s41419-018-1131-7
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
2017 · British Journal of Cancer · 26 citations
https://doi.org/10.1038/bjc.2017.197
Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress
2020 · Cell Death and Differentiation · 18 citations
https://doi.org/10.1038/s41418-020-00655-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat